WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.

Hao Liu,Wei Chen,Chao Liang,Bryan Wei Chen,Xiao Zhi,Shufeng Zhang,Xiaoxiao Zheng,Xueli Bai,Tingbo Liang
DOI: https://doi.org/10.1016/j.canlet.2015.03.001
IF: 9.756
2015-01-01
Cancer Letters
Abstract:•HCC cells with p53 expression displayed enhanced sensitivity.•p53 depletion abolished the synergistic cytotoxicity.•WP1130 co-treatment suppressed doxorubicin-mediated p53 upregulation.•usp9x downregulation abolished the synergistic cytotoxic effects of WP1130.•Tenovin-1 decreased the doxorubicin cytotoxicity in the presence of WP1130.
What problem does this paper attempt to address?